BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

June 16, 2011

View Archived Issues

MEGF-0444A is safe as monotherapy or combined with bevacizumab/paclitaxel in solid tumors

Read More

Interim first-in-human data support immunological efficacy of EMD-640744 in advanced solid tumors

Read More

Takeda presents new agents for treatment of diabetes

Read More

Phase III data on lipegfilgrastim for reduction of neutropenia in breast cancer

Read More

Enrollment complete in phase II CRMD-001 trial in contrast-induced acute kidney injury

Read More

Rozrolimupab well tolerated and active in patients with primary immune thrombocytopenia

Read More

Phase I/II data on navitoclax in lymphoid malignancies updated

Read More

Veliparib/temozolomide combination is safe in metastatic unresectable CRC

Read More

Lithostathine-1-alpha as a new biomarker in rheumatoid arthritis

Read More

Novel photosensitizing agents prepared at Mallinckrodt

Read More

Merck & Co. claims new hydroxycarboxylic acid HCA2 receptor agonists

Read More

Novel acetyl-CoA carboxylase inhibitors prepared by Pfizer

Read More

Roche team synthesizes novel glycogen synthase activators

Read More

Synageva BioPharma and Trimeris enter into merger agreement

Read More

Arecor and GSK join forces to develop new vaccine formulations

Read More

Resverlogix to begin phase IIb ASSURE trial of RVX-208

Read More

Abstral launched in Canada for breakthrough cancer pain

Read More

Dosing begins in first-in-human trial of VIA-3196 for dyslipidemia

Read More

Pathfast cTnI-II (cardiac troponin I) diagnostic test cleared in U.S.

Read More

APR and Labtec regain rights to ondansetron oral dispersible film

Read More

Adaptimmune begins phase I/II trial of genetically modified T-cell therapies in metastatic melanoma

Read More

FDA clears Inform Dual ISH test to help identify candidates for breast cancer therapy Herceptin

Read More

FDA accepts for review Novartis' application to expand Menveo indication to infants and toddlers

Read More

Nulojix approved in U.S. for prevention of acute kidney transplant rejection in adults

Read More

Sprycel indication expanded in Japan to include first-line treatment of chronic myeloid leukemia

Read More

Depakene approved in Japan to suppress onset of migraine attacks

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing